Status:
ENROLLING_BY_INVITATION
A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to collect information for scientific research and to better understand awareness and to understand overall risk awareness, diagnoses and treatment related to liver relate...
Eligibility Criteria
Inclusion
- HCP inclusion criteria
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- Licensed to practice medicine in one of the countries of interest: United States, Canada, France, Germany, Japan
- Must be a practicing endocrinologist, hepatologist, cardiologist, obesity specialist, primary care physician, radiologist, nurse practitioner or physician assistant (NP/PA US only)
- Must be at least "somewhat familiar" (as opposed to "not at all familiar) with Metabolic dysfunction-associated steatohepatitis (MASH) (do not need to be currently treating people with MASH) 6. Must have at least 2 years in practice 7. Must spend at least 50 percentage of their time in patient care
- Diagnosed patient inclusion criteria
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- Diagnosis of MASH or Metabolic Associated Steatotic Liver Disease (MASLD) within past 24 months
- Live in one of the countries of interest: United States, Canada, France, Germany, Japan
- Have at least one comorbid condition: obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease
- At risk patient inclusion criteria
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- Live in one of the countries of interest: United States, Canada, France, Germany, Japan
- Must have one or more risk factors associated with MASH \[obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease\], be diagnosed with steatosis (incidental finding) or have a blood test that shows raised liver enzymes.
Exclusion
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Key Trial Info
Start Date :
October 2 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 23 2025
Estimated Enrollment :
1320 Patients enrolled
Trial Details
Trial ID
NCT07201831
Start Date
October 2 2025
End Date
December 23 2025
Last Update
November 10 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Plainsboro, New Jersey, United States, 08536
2
Novo Nordisk Investigational Site
Mississauga, Canada
3
Novo Nordisk Investigational Site
Puteaux, France
4
Novo Nordisk Investigational Site
Mainz, Germany